Krystal Biotech, Inc. (KRYS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 51 | 291 | 389 | 440 | 507 |
| Operating profit | $m | 161 | 198 | ||||||
| Net profit | $m | -32 | -70 | -140 | 11 | 89 | 205 | 241 | 229 |
| EPS reported | $ | 6.84 | 7.98 | ||||||
| Operating cashflow per share | $ | 6.94 | 9.22 | ||||||
| Capex per share | $ | 0.41 | 0.49 | ||||||
| FCF per share | $ | 6.53 | 8.73 | ||||||
| Free cash flow | $m | 189 | 258 | ||||||
| Net debt | $m | -828 | -839 | ||||||
| Book value equity | $m | 1,220 | 1,359 | ||||||
| Book value per share | $ | 40.72 | 44.33 | ||||||
| Number of shares | m | 29.95 | 30.66 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 36.04 | 43.34 | ||||||
| P/B LTM | x | 5.85 | 5.25 | ||||||
| P/S LTM | x | 18.34 | 16.20 | ||||||
| P/FCF LTM | x | 37.77 | 27.68 | ||||||
| EV/EBITDA LTM | x | 33.92 | 30.44 | ||||||
| EV/Sales LTM | x | 17.09 | 21.29 | ||||||
| Earnings Yield LTM | % | +2.77% | +2.31% | ||||||
| FCF Yield | % | +2.65% | +3.61% | ||||||
| Quality | |||||||||
| ROE | % | +16.80% | +19.34% | ||||||
| ROIC | % | +13.09% | +14.39% | ||||||
| Operating margin | % | +41.45% | +44.93% | ||||||
| Gross margin | % | +92.61% | +93.34% | ||||||
| FCF/Sales | % | +48.55% | +58.52% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +128.00% | +166.00% | ||||||
| Sales Growth YoY | % | +33.94% | +51.62% | ||||||
| Net Income Growth YoY | % | +129.74% | +170.83% | ||||||
| FCF Growth | % | +58.51% | +116.29% | ||||||
| Operating Profit Growth | % | +145.52% | +201.27% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 20.23 | 29.12 | ||||||
| Net Debt/EBITDA | x | -2.48 | -1.92 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.68 | -0.62 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free